Zoya Gluzman-Poltorak Poltorak | CEO
Forta Bio | United States
Dr. Zoya Gluzman-Poltorak is a biotech executive with 25+ years of leadership spanning gene and cell therapy, genome editing, and targeted biologics, advancing multiple programs from early research to the clinic and serving as development lead on seven FDA INDs. She has built and led high-impact cross-functional teams, secured $250M+ in public and private funding, and driven partnerships with BARDA, DoD, NIH, and global research collaborators, supported by a strong record of publications and patents. As Co-Founder and CEO of Forta Bio, a startup pioneering ODCs™- a first-in-class precision DNA/RNA therapeutic modality developed at City of Hope - she is leading fundraising and executing a focused plan to bring Forta’s lead candidate into the clinic in under two years.
Appearances:
Festival of Biologics Day 1 @ 17:30
ODC™: A Novel Class of Targeted and Programmable DNA/RNA Medicines
1. Introduction of ODC™ (Oligonucleotide-Dependent Cytotoxicity): a new class of naked, targeted oligonucleotide therapeutics combining precision delivery, switchable cytotoxicity, and programmable immunomodulation.
2. “ADC concept, upgraded”: ODC™ delivers ADC-like targeted killing with a simpler, programmable oligo platform, backed by a validated MoA, strong preclinical efficacy/safety, and an expedited path to the clinic (FortaOnc™).
3. Integrated FortaGuideAI™ engine for generative, multi-objective ODC design and optimization, continuously learning from high-throughput screening and in vivo results.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events